Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
AD26.COV2.S – Janssen Pharmaceutical Companies leads to lower all‐cause mortalityb compared with placebo (high certainty).
AD26.COV2.S – Janssen Pharmaceutical Companies showed no clear difference in serious adverse eventsb compared with placebo (moderate certainty).
AD26.COV2.S – Janssen Pharmaceutical Companies leads to higher systemic reactogenicity eventse compared with placebo (high certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether gam‐COVID‐VAC – Sputnik V changes all‐cause mortalityf compared with placebo (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Gam‐COVID‐VAC – Sputnik V showed no clear difference in serious adverse eventsf compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
CoronaVac – Sinovac showed no clear difference in all‐cause mortalityh compared with placebo (low certainty).
CoronaVac – Sinovac showed no clear difference in systemic reactogenicity eventsj compared with placebo (low certainty).
CoronaVac – Sinovac leads to higher any adverse evento compared with placebo (high certainty).